Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia

Haematologica

Volumn 95, Issue 7, 2010, Pages 1211-1215

  Belgaumi, Asim F ^a   Al Shehri, Ali ^a   Ayas, Mouhab ^a   Al Mahr, Mohammed ^a   Al Seraihy, Amel ^a   Al Ahmari, Ali ^a   El Solh, Hassan ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Adult studies; BCR ABL; Chronic myeloid leukemia; Stem cell transplantation

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; ETOPOSIDE; HYDROXYUREA; IDARUBICIN; IMATINIB; THYMOCYTE ANTIBODY; TIOGUANINE; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTINUOUS INFUSION; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JOINT LIMITATION; LEG EDEMA; LEG PAIN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MORTALITY; PRESCHOOL CHILD; PROCEDURES;

BENZAMIDES; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77954462994     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.015180     Document Type: Article

References (17)

1. Druker BJ, Lydon LB. Lessons learned from an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000; 105(l):3-7.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. 5-year follow up of patients receiving Imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17.
3. O'Brien SG, Guilhot F, Larson RA,Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med. 2003,348(11):994-1004.
4. Fiochhaus A,Druker BJ,Sawyer C,Guilhot F,Schiffer CA,Cortes J,et al. Favorable long-term follow-up results over 6 years for response, survival and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure with inter-feron-a treatment. Blood. 2008;111(3): 1039-43.
5. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007; 110(8):2828-37.
6. Maziarz RT, Mauro MJ. Transplantation for chronic myelogenous leukemia: yes, no, maybe so.An Oregon experience. Bone Marrow Transplant. 2003;32(5):459-69.
7. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (STI571) for treatment of children with Philadephia chromosome-positive leukemia: results from a Children's Oncology Group Phase I study. Blood. 2004;104(9):2655-60.
8. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT Bone Marrow Transplant. 2008; 42:S40-6.
9. Hehlmann R, Berger U, Pfirrmann M, Heimpel FF, Hocchaus A, Hasford J, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007;109(11):4686-92.
10. Mllot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Bekassy AN, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006;20(2): 187-92.
11. Mchor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature. 2005;435(7046):1267-70.
12. Burke MJ, Willert J, Desai S, Kadota R. The treatment of pediatric Philadelphia positive (Ph+) leukemias in the Imatinib era. Pediatr Blood Cancer. 2009;53(6):992-5.
13. Otazu IB, Tavares RCB, Hassan R, Zalcberg I, Tabak DG, Seuanez HN. Estimations of BCR-ABL/ABL transcripts by quantitative PCR in chronic myeloid leukaemia after allogeneic bone marrow transplantation and donor lymphocyte infusion. Leuk Res. 2002;26(2):129-41.
14. Wen PY, Yung WKA, Lamborn KR Dahia PL, Wang Y, Peng B, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. 2006;12(16): 4899-907.
15. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, di Paola ED, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38 Suppl 5:S83-7.
16. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Rviere GL, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111(8):4022-8.
17. Breccia M, Alimena G. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism. Leuk Res. 2009;33(7):871-5.